Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nitazoxanide + ciclesonide
- Development stage
- Phase 3
- Lead developer
- Drugs for Neglected Diseases initiative
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
A drug combination consisting of the antiparasitic nitazoxanide and the inhaled corticosteroid ciclesonide. This combination was designed to target COVID-19 through two different mechanisms: nitazoxanide potentially acting during the viral replication stage of SARS-CoV-2 infection, and ciclesonide potentially decreasing the likelihood of the inflammatory stage. Both drugs were selected because they were already commercially available and would be affordable and easy to access and administer if proven effective against COVID-19.
02
Targets
CYP2D6 (Cytochrome P450 2D6)GR (Glucocorticoid receptor)NSP6 (SARS-CoV-2 non-structural protein 6)
Beyond the preview
Go deeper on nitazoxanide + ciclesonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nitazoxanide + ciclesonide.